Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 8-K, filed Sep 9, 2026
- Incorporated
- Delaware
- Filings on record
- 342 filings
- On EDGAR
- CIK 1782223
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 21
News 8 of 57
Prospectuses and Registrations 8 of 25
- 424B2 Prospectus supplement for an offering Aug 28, 2026
- S-3 Shelf registration statement Aug 20, 2026
- S-8 Registration statement for an employee plan Mar 23, 2026
- S-3 Shelf registration statement Nov 26, 2025
- S-8 Registration statement for an employee plan Mar 18, 2025
- S-8 Registration statement for an employee plan Nov 12, 2024
- 424B2 Prospectus supplement for an offering Apr 4, 2024
- S-3 Shelf registration statement Mar 27, 2024
Proxies 8 of 12
- DEFA14A Extra proxy material Apr 30, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2026
- DEFA14A Extra proxy material Apr 29, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 29, 2025
- DEF 14A Proxy statement for a shareholder vote Sep 25, 2024
- PRE 14A Preliminary proxy statement Sep 13, 2024
- DEFA14A Extra proxy material Apr 26, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2024
Ownership 8 of 181
- 4 Insider reported a trade Sep 8, 2026
- 4 Insider reported a trade Aug 20, 2026
- 4 Insider reported a trade Aug 14, 2026
- 3 Insider reported their initial holding Jul 10, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 10, 2026
- 4 Insider reported a trade Jul 2, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Jul 2, 2026
- 144 Notice of a proposed sale of restricted stock Jun 30, 2026
Other 8 of 46
- EFFECT Notice that a registration became effective Aug 27, 2026
- ARS Annual report sent to shareholders Apr 30, 2026
- EFFECT Notice that a registration became effective Dec 9, 2025
- CORRESP Reply to SEC staff Dec 8, 2025
- ARS Annual report sent to shareholders Apr 26, 2024
- EFFECT Notice that a registration became effective Apr 3, 2024
- CORRESP Reply to SEC staff Apr 1, 2024
- UPLOAD Comment letter from SEC staff Mar 29, 2024
Everything here comes from Pyxis Oncology, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.